Valuation: Beam Therapeutics Inc.

Market Cap 2.5B 2.19B 2.04B 1.87B 3.52B 241B 3.57B 24.23B 9.47B 118B 9.38B 9.18B 409B P/E 2026 *
-5.78x
P/E 2027 * -5.53x
Enterprise Value 1.64B 1.44B 1.34B 1.23B 2.31B 158B 2.35B 15.94B 6.23B 77.83B 6.17B 6.04B 269B EV / Sales 2026 *
20.8x
EV / Sales 2027 * 13.8x
Free-Float
98.6%
Yield 2026 *
-
Yield 2027 * -
1 day-3.13%
1 week-8.83%
Current month-26.86%
1 month-26.02%
3 months-7.41%
6 months-20.47%
Current year-9.45%
1 week 24.85
Extreme 24.85
28.13
1 month 24.85
Extreme 24.85
38.26
Current year 21.63
Extreme 21.63
38.26
1 year 15.6
Extreme 15.6
38.26
3 years 13.52
Extreme 13.525
49.5
5 years 13.52
Extreme 13.525
116.91
10 years 13
Extreme 13
138.52
Manager TitleAgeSince
Chief Executive Officer 48 31/12/2016
Director of Finance/CFO 48 18/12/2024
President 57 23/01/2020
Director TitleAgeSince
Director/Board Member 48 31/12/2016
Director/Board Member 75 30/04/2018
Director/Board Member 56 09/10/2019
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Fiscal year

Chief Executive Officer

75,000 0.0729%
30/06/26 Sell

Chief Technology Officer

-373 0.0004%
26/06/26
F-Prime Inc.
SellCompany -251,488 0.2444%
Change 5-day change 1-year change 3-year change Capi.($)
-3.13%-8.83%+15.56%-22.67% 2.5B
+1.07%-3.49%-3.35%+10.44% 46.86B
+0.25%+1.65%+399.22%+634.87% 40.23B
-0.27%+4.45%+11.81%+65.64% 36.23B
+0.35%+0.87%+4.46%-10.16% 34.72B
+3.14%+1.02%+3.37%+38.15% 27.89B
-0.73%+11.84%+34.39%+134.36% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%-3.43%+9.03% 13.12B
-2.68%-2.49%-11.36%-33.61% 12.7B
Average -0.11%-0.14%+50.07%+91.79% 24.78B
Weighted average by Cap. +0.44%+0.81%+73.61%+134.22%

Financials

2026 *2027 *
Net sales 78.87M 69.27M 64.42M 59.11M 111M 7.6B 113M 765M 299M 3.73B 296M 290M 12.91B 96.07M 84.38M 78.47M 72.01M 135M 9.25B 137M 932M 364M 4.55B 361M 353M 15.73B
Net income -461M -405M -377M -346M -649M -44.41B -659M -4.47B -1.75B -21.83B -1.73B -1.69B -75.48B -521M -457M -425M -390M -733M -50.15B -745M -5.05B -1.97B -24.66B -1.95B -1.91B -85.25B
Net Debt -855M -751M -698M -641M -1.2B -82.29B -1.22B -8.29B -3.24B -40.46B -3.21B -3.14B -140B -1.17B -1.03B -957M -878M -1.65B -113B -1.68B -11.37B -4.44B -55.48B -4.4B -4.3B -192B
Logo Beam Therapeutics Inc.
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Employees
522
Date Price Change Volume
24/07/26 US$25.10 -3.13% 1,810,181
23/07/26 US$25.91 -2.74% 2,957,728
22/07/26 US$26.64 -2.38% 1,545,437
21/07/26 US$27.29 +3.65% 1,854,704
20/07/26 US$26.33 -4.36% 2,767,990
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
25.10USD
Average target price
52.31USD
Spread / Average Target
+108.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BEAM Stock